CagriSema manufacturer Novo Nordisk is the only company developing this amylin-plus-semaglutide combination. Learn its status, trials, and sourcing facts.
CagriSema is manufactured by Novo Nordisk. The Danish pharmaceutical company is the sole originator and rights holder for the combination of cagrilintide and semaglutide, and no other company is licensed to produce it. As of 2025, CagriSema remains an investigational drug that has not been approved by the FDA or any other regulator worldwide.
That single-source reality shapes almost everything about the product: its availability, its price, and the flood of unofficial listings that appear when a drug is still in late-stage trials.
Who Is the CagriSema Manufacturer?
Novo Nordisk developed both active ingredients in the combination, which is why cagrisema novo nordisk is essentially the only pairing of those two words that reflects reality. No third-party manufacturer, contract lab, or compounding pharmacy holds rights to the finished product.
- Cagrilintide — a long-acting amylin analog developed in-house by Novo Nordisk.
- Semaglutide — the GLP-1 receptor agonist the company already markets as Ozempic, Wegovy, and Rybelsus.
Owning both molecules gives Novo Nordisk complete control over production and pricing. That is unusual in the peptide world, where dozens of labs compete for the same catalog. A thymosin alpha 1 manufacturer, for example, competes with many peers selling a nearly identical product. CagriSema has one source and one source only.
What CagriSema Is and How It Works
CagriSema is a fixed-dose combination designed to hit two appetite pathways at once. Amylin analogs slow gastric emptying and signal fullness to the brain, while GLP-1 agonists reduce appetite and improve blood sugar control.
In the clinical program, the studied regimen was a once-weekly cagrisema injection delivering 2.4 mg cagrilintide plus 2.4 mg semaglutide, reached through gradual dose escalation. Any cagrisema dosage chart circulating online reflects trial protocols or speculation rather than approved labeling, because no approved label exists yet.
The drug is delivered subcutaneously, most likely with a pen device similar to the ones Novo Nordisk already produces for Wegovy.
Clinical Trial Results and Approval Status
Novo Nordisk ran the REDEFINE phase 3 program, and the headline numbers are the main reason this drug gets so much attention.
- REDEFINE 1 (adults with obesity or overweight without diabetes): roughly 22.7% average weight loss at 68 weeks, with about 40% of participants losing 25% or more of their body weight.
- REDEFINE 2 (adults with type 2 diabetes and overweight or obesity): about 15.7% average weight loss at 68 weeks, compared with roughly 3.1% on placebo.
The most common tolerability complaints were gastrointestinal, and the profile looked broadly consistent with existing GLP-1 medicines. Novo Nordisk has signaled plans for regulatory submissions in 2026.
CagriSema is not FDA-approved for any indication, and it cannot be legally prescribed or dispensed in the United States today.
How CagriSema Compares to Other Weight-Loss Drugs
Side-by-side comparisons such as retatrutide vs cagrisema come up often, so it helps to see the field in one place. Note that only two of these products are currently approved.
| Product | Manufacturer | Mechanism | Status | Reported weight loss |
|---|---|---|---|---|
| CagriSema | Novo Nordisk | Amylin analog + GLP-1 | Investigational | ~22.7% at 68 weeks (REDEFINE 1) |
| Wegovy (semaglutide) | Novo Nordisk | GLP-1 | FDA-approved | ~15% at 68 weeks (STEP 1) |
| Zepbound (tirzepatide) | Eli Lilly | GIP + GLP-1 | FDA-approved | ~21% at 72 weeks (SURMOUNT-1) |
| Retatrutide | Eli Lilly | GIP + GLP-1 + glucagon | Investigational | ~24% at 48 weeks (phase 2) |
Cross-trial comparisons always have limits, because study populations, durations, and dose-escalation schedules differ. Even so, CagriSema sits at the high end of the efficacy range among injectable obesity treatments.
Why "Research Grade" CagriSema Listings Are a Red Flag
Search results for this drug frequently surface vendors selling lyophilized "research grade" powder. These products are not made by Novo Nordisk, and Novo Nordisk does not sell CagriSema as a research chemical.
Unapproved peptides sold online are not subject to FDA manufacturing standards, sterility testing, or independent potency verification. A vial labeled as CagriSema may contain semaglutide alone, a different peptide entirely, or an unknown quantity of the stated compound. Anyone researching cagrisema where to buy should understand that no legal retail supply exists while the drug is investigational.
Legitimate clinical access, when it exists at all, happens through an enrolled trial site rather than an online storefront.
Safety and Side Effects to Understand
Because cagrilintide and semaglutide act on overlapping appetite pathways, the gastrointestinal burden tends to be the main issue. Reported cagrisema side effects in trials were mostly mild to moderate and included nausea, vomiting, diarrhea, and constipation, especially during dose escalation.
GLP-1 and amylin-based therapies also carry class warnings for gallbladder disease, pancreatitis, and loss of lean muscle mass during rapid weight loss. These drugs are not appropriate during pregnancy, and they require medical supervision for anyone with a history of thyroid cancer, kidney disease, or diabetic retinopathy.
Anyone considering a GLP-1 or amylin-based treatment should talk with a licensed healthcare professional about personal risks, monitoring, and realistic expectations rather than relying on forum reports.
What to Expect on Price and Availability
Novo Nordisk has not announced cagrisema price, and pricing will not be public until an approval decision is close. For context, approved weekly GLP-1 obesity medications list above $1,000 per month before insurance, rebates, or savings programs.
Timing depends on regulatory review. Assuming submissions in 2026, a US approval decision would most plausibly land in late 2026 or 2027, with commercial launch following shortly after.
Until then, the accurate answer to "who makes CagriSema" stays the same: Novo Nordisk, and only Novo Nordisk.
Frequently Asked Questions
Who manufactures CagriSema?
CagriSema is developed and manufactured by Novo Nordisk. The company owns both components, cagrilintide and semaglutide, so no other manufacturer is licensed to produce the combination.
Is CagriSema available in the United States?
No. CagriSema is still an investigational drug and is not FDA-approved for any use in the United States. It cannot be legally prescribed or sold at retail while it remains under regulatory review.
How effective is CagriSema compared with other weight-loss drugs?
In the REDEFINE 1 trial, participants without diabetes lost an average of about 22.7% of their body weight at 68 weeks. That places CagriSema at the higher end of injectable obesity treatments, though cross-trial comparisons are not definitive because study designs differ.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.